This study indicated that epileptogenicity in malignant glioma requires the co-existence and reciprocal expression of CD44 and xCT, so both could be potential targets for anti-epileptic and anti-tumoral therapies in GBM. This evidence concerns the gene SLC7A11 and glioblastoma.